Open AccessTargeted Therapies in HER2-Overexpressing Metastatic Breast Cancer
Author(s) -
Soumaya Labidi,
Nesrine Mejri,
Aymen Lagha,
Nouha Daoud,
Houda El Benna,
Mehdi Afrit,
Hamouda Boussen
Publication year - 2016
Publication title -
breast care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.767
H-Index - 30
eISSN - 1661-3805
pISSN - 1661-3791
DOI - 10.1159/000452194
Subject(s) - medicine , lapatinib , pertuzumab , trastuzumab emtansine , trastuzumab , metastatic breast cancer , human epidermal growth factor receptor 2 , oncology , breast cancer , adjuvant , cancer , disease
Human epidermal growth factor receptor-2 (HER2) is amplified in 25-30% of breast cancers and is associated with aggressive disease and poorer survival. Multiple anti-HER2 targeted therapies have dramatically changed management and outcome of this subgroup, both in adjuvant and metastatic settings. Despite the improvement of survival thanks to trastuzumab, unclear mechanisms of resistance occur, which has led to the development of new anti-HER2 therapies such as lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1). The optimal sequence of the available drugs is still not well established. All this progress raises the question of toxicity that need to be managed, especially with longer survival of patients. In this article, we review different anti-HER2 therapies used in HER2-positive m etastatic breast cancer.